Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

---

BEKSAÇ M., Seval G. C. , PAYDAŞ S., Tuglular T. F. , ARSLAN Ö., GÖKER H., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.10, 2019 (Journal Indexed in SCI)

• Publication Type: Article / Abstract
• Volume: 19 Issue: 10
• Publication Date: 2019
• Doi Number: 10.1016/j.clml.2019.09.402
• Title of Journal : CLINICAL LYMPHOMA MYELOMA & LEUKEMIA